title: Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study.
abstract: OBJECTIVE
  To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors.
  
  
  METHODS
  A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery.
  
  
  RESULTS
  The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05).
  
  
  CONCLUSIONS
  Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
authors.affiliation: Consultation Psychiatry & Behavioural Epidemiology Unit, Cotugno Hospital, Napoli, Italy. starace@libero.it
authors.forename: F
authors.initials: F
authors.lastname: Starace
authors.forename: L
authors.initials: L
authors.lastname: Bartoli
authors.forename: M S
authors.initials: MS
authors.lastname: Aloisi
authors.forename: A
authors.initials: A
authors.lastname: Antinori
authors.forename: P
authors.initials: P
authors.lastname: Narciso
authors.forename: G
authors.initials: G
authors.lastname: Ippolito
authors.forename: L
authors.initials: L
authors.lastname: Ravasio
authors.forename: M C
authors.initials: MC
authors.lastname: Moioli
authors.forename: D
authors.initials: D
authors.lastname: Vangi
authors.forename: L
authors.initials: L
authors.lastname: Gennero
authors.forename: O V
authors.initials: OV
authors.lastname: Coronado
authors.forename: A
authors.initials: A
authors.lastname: Giacometti
authors.forename: S
authors.initials: S
authors.lastname: Nappa
authors.forename: M L
authors.initials: ML
authors.lastname: Perulli
authors.forename: V
authors.initials: V
authors.lastname: Montesarchio
authors.forename: A
authors.initials: A
authors.lastname: La Gala
authors.forename: F
authors.initials: F
authors.lastname: Ricci
authors.forename: L
authors.initials: L
authors.lastname: Cristiano
authors.forename: M
authors.initials: M
authors.lastname: De Marco
authors.forename: C
authors.initials: C
authors.lastname: Izzo
authors.forename: P
authors.initials: P
authors.lastname: Pezzotti
authors.forename: A
authors.initials: A
authors.lastname: D'Arminio Monforte
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D003072:Cognition Disorders / Q000209:etiology* / Q000523:psychology; D003863:Depression; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000523:psychology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000209:etiology* / Q000523:psychology; D015995:Prevalence